You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 97 No. 2, August 1968 TABLE OF CONTENTS
  Archives
  •  Online Features
  Papers Read at the Twenty-Fifth Annual Meeting of the Central Surgical Association Cleveland, Feb 22-24, 1968 Part 1
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Antilymphoid Sera in Renal Allotransplantation

Roy G. Shorter, MD; George A. Hallenbeck, MD; Carlos Nava, MD; Hugh O. O'Kane, MB, BSc, FRCS; James H. DeWeerd, MD; William J. Johnson, MD

AMA Arch Surg. 1968;97(2):323-329.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

BECAUSE of observations by others1-7 on the effects of heterologous antilymphoid sera (ALS) and experiences in the laboratory with the use of antithymus serum as the single immunosuppressive agent in achieving prolongation of survival of allografts of skin (P. Sutthiwan et al, unpublished data) and xenografts of tumor in mice8 we decided to test the immunosuppressive effects of such sera in the allografting of livers and kidneys in dogs, and subsequently to proceed with a trial of the material in the clinical renal transplant program at the Mayo Clinic. The experiments involving hepatic allografting in dogs have been reported elsewhere,9 and the purposes of this presentation are to describe the results obtained in canine renal allografting and to review the findings of a preliminary clinical trial in human beings. In animals, the sera were used as the sole means of immunosuppression; in the clinical situation, however, testing . . . [Full Text PDF of this Article]


Author Affiliations

Rochester, Minn

From the sections of organ and tissue transplantation (Drs. Shorter and Hallenbeck), urology (Dr. Deweerd), and nephrology (Dr. Johnson), Mayo Clinic and Foundation, and sections of surgery (Dr. Nava), and surgical research (Dr. O'Kane), Mayo Graduate School of Medicine (University of Minnesota), Rochester.


Footnotes

Submitted for publication March 22, 1968.

Read before the 25th annual meeting of the Central Surgical Association, Cleveland, Feb 23, 1968.

Reprint requests to Mayo Clinic, 200 First St SW, Rochester, Minn 55901.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1968 American Medical Association. All Rights Reserved.